Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides

Nature Medicine

Volumn 1, Issue 11, 1995, Pages 1179-1183

  Mandelboim, Ofer ^a   Vadai, Ezra ^a   Fridkin, Mati ^b   Katz Hillel, Anne ^a   Feldman, Michael ^a   Berke, Gideon ^a   Eisenbach, Lea ^a  

^a Department of Cell Biology ^*  (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; PEPTIDE; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; INTRADERMAL DRUG ADMINISTRATION; LUNG CARCINOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMAL; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; IMMUNOTHERAPY; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 0028884728     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1195-1179     Document Type: Article

References (21)

1. Urban, J.L. & Schreiber, H. Tumor antigens. Annu. Rev. Immun. 10, 617-644 (1992).
2. Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony-stimulating factor stimulates potent, specific and long lasting anti-tumor immunity. Proc. natn. Acad. Sci. U.S.A. 90, 3539-3543 (1993).
3. Melief, C.J. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res. 58, 143-175 (1992).
4. Rosenberg, S.A. et al. Use of tumor infiltrating lymphocytes and interlukin-2 in the immunotherapy of patients with metastatic melanoma. New Engl. J. Med. 319, 1676-1680 (1988).
5. Boon, T., Cerottini, J.C., Van Der Eynde, B., Van Der Brugenn, P. & Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu Rev. Immun. 12, 337-365(1994).
6. Mandelboim, O. et al. CTL induction by a tumor associated antigen octapep-tide derived from a murine lung carcinoma Nature 369, 67-71 (1994).
7. h gene. Proc. natn. Acad Sci. U.S.A. 85, 4463-4467 (1988).
8. Sette, A. et al. Antigen analogs/MHC complexes as specific T cell receptor antagonists. Annu. Rev. Immun. 12, 413 (1994).
9. Rock, K.L., Rothstein, L., Gamble, S. & Fleischacker, F. Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J. Immun. 150, 438-446 (1993).
10. Kovacsovics-Bankowski, M. & Rock, K.L, A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267, 243-246 (1995).
11. Levitski, H.I., Lazenby, A., Hayashi, R.J., Pardoll, D.M. In vivo priming of two distinct anti tumor effectors populations: The role of MHC class I expression. J. exp. Med. 179, 1215-1224 (1994).
12. Kunding, T.M. et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268, 1343-1346 (1995).
13. Kast, W.M., Brandt, R.M. & Melief, CJ. Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated anti viral protection by peptide vaccination. Eur. I. Immun. 23, 1189-1192 (1993).
14. Schultz, M., Zingemagel, R.M. & Hengarther, H. Peptide-induced anti viral protection by cytotoxic T cells. Proc. natn. Acad. Sci. U.S.A. 88, 991-993 (1991).
15. North, R.J. & Awwad, M. Elimination of cycling CD4* suppressor T cells with an anti-mltotic drug releases non-cycling CD8* T cells to cause regression of an advanced lymphoma. Immunol. 71, 90-95 (1990).
16. Rakmilevich, A.L. & North, R.J. Elimination of CD4’ T cells in mice bearing advanced sarcoma augments the anti tumor action of interleukin-2. Cancer Immun. Immunother. 38, 197-112 (1994).
17. Rakmilevich, A.L. & North, R.J. & Dye, E.S. Presence of CD4* T suppressor cells in mice endeared unresponsive to tumor antigens by intravenous injection of irradiated tumor cells. Int. J. Cancer. 53, 338-343 (1993).
18. Awwad, M., North, R.J. Cydopohsphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: A consequence of eliminating precursor L3T4* suppressor T-cells. Cancer Res. 49, 1649-1654 (1989).
19. Gelber, C., Eisenbach, L., Feldman, M. & Goodenow, R.S. T-cell subset analysis of Lewis lung carcinoma tumor rejection: Heterogeneity of effectors and evidence for negative regulatory lymphocytes correlating with metastasis. Cancer Res. 52, 6507-6515 (1992).
20. Powrie, F. & Coffman R.L. Cytokine regulation of T-cell function: Potential for therapeutic intervention. Immun. Today 14, 270-273 (1993).
21. Feltkamp, M.C.W. et al. Vaccination with cytotoxic T lymphocyte epitope-contaning peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immun. 23, 2242-2249 (1993).